Journal Home > Volume 1 , Issue 1

menu
Full text
Outline
About this article

Interpretation of the diagnosis and treatment protocol for COVID‐19 (Trial Version 9)

Show Author's information Jiang Rongmeng1 ( )
Beijing Ditan Hospital, Capital Medical University, Beijing, China
Keywords: treatment, diagnosis, protocol, COVID‐19

References(9)

NHC. COVID‐19 Diagnosis and Treatment Protocol (Trial Version 3) [EB/OL].(2020). Available from: http://www.nhc.gov.cn/yzygj/s7653p/202001/f492c9153ea9437bb587ce2ffcbee1fa/files/39e7578d85964dbe81117736dd789d8f.pdf
NHC. COVID‐19 Diagnosis and Treatment Protocol (Trial Version 4) [EB/OL]. (2020). Available from: http://www.nhc.gov.cn/yzygj/s7653p/202001/4294563ed35b43209b31739bd0785e67/files/7a9309111267475a99d4306962c8bf78.pdf
NHC. COVID‐19 Diagnosis and Treatment Protocol (Trial Version 5) [EB/OL]. (2020). Available from: http://www.nhc.gov.cn/yzygj/s7653p/202002/3b09b894ac9b4204a79db5b8912d4440/files/7260301a393845fc87fcf6dd52965ecb.pdf
NHC. COVID‐19 Diagnosis and Treatment Protocol (Trial Version 6) [EB/OL]. (2020). Available from: http://www.nhc.gov.cn/yzygj/s7653p/202002/8334a8326dd94d329df351d7da8aefc2/files/b218cfeb1bc54639af227f922bf6b817.pdf
DOI
NHC. COVID‐19 Diagnosis and Treatment Protocol (Trial Version 7). (2020). NHC Office Medical Letter [2020] No. 184. Available from: http://www.nhc.gov.cn/yzygj/s7653p/202003/46c9294a7dfe4cef80dc7f5912eb1989/files/ce3e6945832a438eaae415350a8ce964.pdf
NHC. COVID‐19 Diagnosis and Treatment Protocol (Trial Version 8). (2020). NHC Office Medical Letter [2020] No. 680. Available from: http://www.nhc.gov.cn/yzygj/s7653p/202008/0a7bdf12bd4b46e5bd28ca7f9a7f5e5a/files/a449a3e2e2c94d9a856d5faea2ff0f94.pdf
NHC. Notification on the issuance of COVID‐19 Diagnosis and Treatment Protocol (Trial Version 9). NHC Office Medical Letter (2022) No. 71. Available from: http://www.nhc.gov.cn/yzygj/s7653p/202203/b74ade1ba4494583805a3d2e40093d88.shtml
Hammond J, Leister‐Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, et al. Oral nirmatrelvir for high‐risk, nonhospitalized adults with COVID‐19. N Engl J Med (2022), 386, 1397‐408.
Self WH, Sandkovsky U, Reilly CS, Vock DM, Gottlieb RL, Mack M, et al. Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII‐196 plus BRII‐198, for adults hospitalised with COVID‐19 (TICO): a randomised controlled trial. Lancet Infect Dis (2021), 22, 622‐35.
Publication history
Copyright
Acknowledgements
Rights and permissions

Publication history

Received: 04 May 2022
Accepted: 15 June 2022
Published: 08 July 2022
Issue date: August 2022

Copyright

© 2022 The Authors.

Acknowledgements

None.

Rights and permissions

This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

Return